XML 35 R22.htm IDEA: XBRL DOCUMENT v3.23.3
Revenues (Tables)
 9 Months Ended
Sep. 29, 2023
Revenue from Contract with Customer [Abstract]  
Schedule of Disaggregation of Revenue
Revenues consisted of the following (in thousands):
Three Months Ended September 30,Nine Months Ended September 30,
2023202220232022
Product revenues:
Gross product revenues$590,442 $496,141 $1,674,937 $1,427,451 
Discounts and allowances(163,945)(129,659)(475,394)(403,627)
Net product revenues426,497 366,482 1,199,543 1,023,824 
Collaboration revenues:
License revenues42,367 34,384 133,406 123,977 
Collaboration services revenues3,056 10,872 17,607 39,344 
Total collaboration revenues45,423 45,256 151,013 163,321 
Total revenues$471,920 $411,738 $1,350,556 $1,187,145 
Net product revenues by product were as follows (in thousands):
Three Months Ended September 30,Nine Months Ended September 30,
2023202220232022
CABOMETYX$422,155 $361,385 $1,187,220 $1,003,356 
COMETRIQ4,342 5,097 12,323 20,468 
Net product revenues$426,497 $366,482 $1,199,543 $1,023,824 
Schedule of Concentration Risks
The percentage of total revenues by customer who individually accounted for 10% or more of our total revenues were as follows:
Three Months Ended September 30,Nine Months Ended September 30,
2023202220232022
Affiliates of McKesson Corporation18 %18 %17 %18 %
Affiliates of AmerisourceBergen Corporation18 %18 %17 %16 %
Affiliates of CVS Health Corporation17 %19 %17 %17 %
Accredo Health, Incorporated12 %11 %12 %10 %
Affiliates of Optum Specialty Pharmacy10 %9 %10 %9 %
Ipsen Pharma SAS8 %8 %8 %11 %
The percentage of trade receivables by customer who individually accounted for 10% or more of our trade receivables were as follows:
September 30, 2023December 31, 2022
Affiliates of McKesson Corporation22 %22 %
Affiliates of AmerisourceBergen Corporation19 %18 %
Ipsen Pharma SAS18 %20 %
Affiliates of CVS Health Corporation14 %18 %
Cardinal Health, Inc.9 %11 %
Schedule of Revenues Disaggregated by Geographic Region
Revenues by geographic region were as follows (in thousands):
Three Months Ended September 30,Nine Months Ended September 30,
2023202220232022
U.S.$429,605 $369,480 $1,213,089 $1,033,160 
Europe36,021 34,818 106,286 131,585 
Japan6,294 7,440 31,181 22,400 
Total revenues$471,920 $411,738 $1,350,556 $1,187,145 
Schedule of Activities and Ending Reserve Balances for Significant Categories of Discounts and Allowances
The activities and ending reserve balances for each significant category of discounts and allowances, which constitute variable consideration, were as follows (in thousands):
Chargebacks, Discounts for Prompt Payment and Other
Other Customer Credits/Fees and Co-pay Assistance
Rebates
Total
Balance at December 31, 2022
$26,881 $14,924 $35,426 $77,231 
Provision related to sales made in:
Current period308,103 40,923 129,922 478,948 
Prior periods293 (1,168)(2,679)(3,554)
Payments and customer credits issued(313,660)(38,497)(124,477)(476,634)
Balance at September 30, 2023
$21,617 $16,182 $38,192 $75,991 
Schedule of Other Assets and Other Liabilities Contract assets and liabilities were as follows (in thousands):
September 30, 2023December 31, 2022
Contract assets (1)
$635 $1,659 
Contract liabilities:
Current portion (2)
$6,974 $7,488 
Long-term portion (3)
6,371 6,582 
Total contract liabilities$13,345 $14,070 
____________________
(1) Presented in other long-term assets in the accompanying Condensed Consolidated Balance Sheets.
(2) Presented in other current liabilities in the accompanying Condensed Consolidated Balance Sheets.
(3) Presented in other long-term liabilities in the accompanying Condensed Consolidated Balance Sheets.